{
  "directed": true,
  "graph": {
    "annotation_list": {},
    "annotation_pattern": {
      "Species": "^\\d+$"
    },
    "annotation_url": {
      "Anatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno",
      "Cell": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno",
      "CellLine": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20170511.belanno",
      "Confidence": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno",
      "Disease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno"
    },
    "document_metadata": {
      "authors": "Trusha Adeshara",
      "contact": "charles.hoyt@scai.fraunhofer.de",
      "copyright": "Copyright © 2019 Fraunhofer Institute SCAI, All rights reserved.",
      "description": "",
      "licenses": "CC BY 4.0",
      "name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington’s Disease",
      "version": "1.0.0"
    },
    "namespace_pattern": {},
    "namespace_url": {
      "CHEBI": "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/chebi-names.belns",
      "CONSO": "https://raw.githubusercontent.com/pharmacome/conso/3c93a65dc48e6786fe29ae55aa36cf9a902fe8c6/export/conso-names.belns",
      "DOID": "https://raw.githubusercontent.com/pharmacome/conso/c0c576e3d3ab9b25a3982251a4ee2fd7c49e1679/external/doid-names.belns",
      "DRUGBANK": "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/drugbank-names.belns",
      "GO": "https://raw.githubusercontent.com/pharmacome/conso/d9d270e11aac480542c412d4222983a5f042b8ae/external/go-names.belns",
      "HGNC": "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/hgnc-names.belns",
      "HGNCGENEFAMILY": "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/hgnc.genefamily-names.belns",
      "HP": "https://raw.githubusercontent.com/pharmacome/conso/d9d270e11aac480542c412d4222983a5f042b8ae/external/hp-names.belns",
      "MESH": "https://raw.githubusercontent.com/pharmacome/conso/f02c6ad4a4791a8ed45448513b9de8c8f1b00c87/external/mesh-names.belns"
    },
    "path": "huntington/sarantos2012.bel",
    "pybel_version": "0.14.10"
  },
  "links": [
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "Htt is involved in a variety of cellular functions including vesicle transport, transcription, and energy metabolism [1,2]. Deletion of the Htt gene in mouse results in embryonic lethality indicating that it is required for development [3].",
      "key": "5bdc602f2a751496a474d867e8770dcf",
      "line": 78,
      "relation": "increases",
      "source": 54,
      "target": 69
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "Htt is involved in a variety of cellular functions including vesicle transport, transcription, and energy metabolism [1,2]. Deletion of the Htt gene in mouse results in embryonic lethality indicating that it is required for development [3].",
      "key": "c9093a66453762e5657b97508e7ca297",
      "line": 79,
      "relation": "increases",
      "source": 54,
      "target": 26
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "Htt is involved in a variety of cellular functions including vesicle transport, transcription, and energy metabolism [1,2]. Deletion of the Htt gene in mouse results in embryonic lethality indicating that it is required for development [3].",
      "key": "9a6fff89e024e387769b0391f3f764f0",
      "line": 80,
      "relation": "increases",
      "source": 54,
      "target": 73
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "Htt is involved in a variety of cellular functions including vesicle transport, transcription, and energy metabolism [1,2]. Deletion of the Htt gene in mouse results in embryonic lethality indicating that it is required for development [3].",
      "key": "97149b16b5cb4b52ebf0c40b6419f907",
      "line": 82,
      "relation": "increases",
      "source": 54,
      "target": 25
    },
    {
      "key": "0ce6657d55cebf519ec5f8609a572687",
      "relation": "hasVariant",
      "source": 54,
      "target": 55
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "A common downstream signaling pathway disrupted in HD is the extracellular signalregulated-kinase (ERK) pathway (also known as the mitogen-activated protein kinase or MAPK pathway) [8].",
      "key": "9bc930e4d36d0392e82d062321ee67f0",
      "line": 87,
      "relation": "negativeCorrelation",
      "source": 71,
      "target": 23
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "7215": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "EGFR-induced ERK activation is disrupted in a Drosophila model of HD [10] and ERK activation is impaired after stimulation with EGF or NGF in PC12 cells expressing mutant huntingtin [11].",
      "key": "843c88c28dcfaf9ff931d11bd560f7b8",
      "line": 109,
      "relation": "negativeCorrelation",
      "source": 71,
      "target": 23
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Huntington's disease": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "To evaluate potential therapeutic effects of pizotifen treatment in vivo , we measured motor function in HD transgenic R6/2 mice after treatment. Pizotifen (7.5 mg/kg or 10mg/kg) or saline was administered by daily IP injection starting at 6 weeks of age...The lack of effect on open-field behavior suggests that the improved rotarod performance is not simply due to acute effects on activity levels but instead to improved motor coordination.",
      "key": "f3addb18a6815246772accc7044b24e5",
      "line": 286,
      "relation": "decreases",
      "source": 71,
      "target": 27
    },
    {
      "annotations": {
        "Anatomy": {
          "striatum": true
        },
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "By immunohistochemistry (IHC), we found that levels of DARPP-32 in the striatum of the HD transgenic R6/2 mice were reduced at 10 weeks of age qualitatively. Pizotifen treatment increased DARPP-32 staining in the striatum at this time point (Figure 8 A ).",
      "key": "1a1984e1bef8d9e7708372ff2fec2761",
      "line": 311,
      "relation": "decreases",
      "source": 71,
      "target": 67
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "We evaluated several of the well-characterized receptors that are altered in HD including D2DR, GAD65/67, GluR2/3 and 5HT1B.",
      "key": "789e17483f50fdd9052ef42c3a00c471",
      "line": 333,
      "relation": "association",
      "source": 71,
      "target": 42
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "D2DR, GAD65/67 and 5HT1B levels are also altered in the HD transgenic R6/2 mice, but pizotifen treatment did not normalize the levels (data not shown).",
      "key": "5340dc6171963c32993b7607a9268dc7",
      "line": 358,
      "relation": "association",
      "source": 71,
      "target": 42
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "We evaluated several of the well-characterized receptors that are altered in HD including D2DR, GAD65/67, GluR2/3 and 5HT1B.",
      "key": "74891041deb0b0c375ab5c92b53e3965",
      "line": 334,
      "relation": "association",
      "source": 71,
      "target": 46
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "D2DR, GAD65/67 and 5HT1B levels are also altered in the HD transgenic R6/2 mice, but pizotifen treatment did not normalize the levels (data not shown).",
      "key": "b462455e96a0a3e6d5b5ff1bcddcbb25",
      "line": 359,
      "relation": "association",
      "source": 71,
      "target": 46
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "We evaluated several of the well-characterized receptors that are altered in HD including D2DR, GAD65/67, GluR2/3 and 5HT1B.",
      "key": "fd4971a1d9623d356bf7ca5b8c491329",
      "line": 335,
      "relation": "association",
      "source": 71,
      "target": 45
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "D2DR, GAD65/67 and 5HT1B levels are also altered in the HD transgenic R6/2 mice, but pizotifen treatment did not normalize the levels (data not shown).",
      "key": "57c162f6c96c9b54fbc9fcc2097b577f",
      "line": 360,
      "relation": "association",
      "source": 71,
      "target": 45
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "We evaluated several of the well-characterized receptors that are altered in HD including D2DR, GAD65/67, GluR2/3 and 5HT1B.",
      "key": "1d00ee0698377d46b24179c90380bc29",
      "line": 336,
      "relation": "association",
      "source": 71,
      "target": 47
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "We evaluated several of the well-characterized receptors that are altered in HD including D2DR, GAD65/67, GluR2/3 and 5HT1B.",
      "key": "a345db699490eaa5bfbac6d22dc6f804",
      "line": 337,
      "relation": "association",
      "source": 71,
      "target": 48
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "We evaluated several of the well-characterized receptors that are altered in HD including D2DR, GAD65/67, GluR2/3 and 5HT1B.",
      "key": "bd8a86a3857a1db7a3b88915cdfdd516",
      "line": 338,
      "relation": "association",
      "source": 71,
      "target": 53
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "D2DR, GAD65/67 and 5HT1B levels are also altered in the HD transgenic R6/2 mice, but pizotifen treatment did not normalize the levels (data not shown).",
      "key": "a8924be476373a08e6860690e4a684f0",
      "line": 361,
      "relation": "association",
      "source": 71,
      "target": 53
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "The levels of mGluR2/3 in HD transgenic R6/2 mice at 10 weeks of age were slightly reduced and pizotifen treatment modestly increased levels of this receptor.",
      "key": "608485abb52cde0b0742b97438af925e",
      "line": 346,
      "relation": "decreases",
      "source": 71,
      "target": 49
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "The levels of mGluR2/3 in HD transgenic R6/2 mice at 10 weeks of age were slightly reduced and pizotifen treatment modestly increased levels of this receptor.",
      "key": "4b172568ef771c3a0aa4ec65e128ffe9",
      "line": 347,
      "relation": "decreases",
      "source": 71,
      "target": 50
    },
    {
      "annotations": {
        "Anatomy": {
          "striatum": true
        },
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "We confirmed that the striatal area was reduced in the striatum of the HD transgenic R6/2 mice at 10 weeks of age and found that pizotifen treatment attenuated this reduction in striatal area (Figure 8 D ).",
      "key": "67558c51f37b343fc4bd151cd1f5c270",
      "line": 374,
      "relation": "increases",
      "source": 71,
      "target": 28
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "A common downstream signaling pathway disrupted in HD is the extracellular signalregulated-kinase (ERK) pathway (also known as the mitogen-activated protein kinase or MAPK pathway) [8].",
      "key": "a4a7b1e4a2567d5e4af64b7dbe25abae",
      "line": 87,
      "relation": "negativeCorrelation",
      "source": 23,
      "target": 71
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "7215": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "EGFR-induced ERK activation is disrupted in a Drosophila model of HD [10] and ERK activation is impaired after stimulation with EGF or NGF in PC12 cells expressing mutant huntingtin [11].",
      "key": "c5b9f1cf07d030eeb95e7b4374617908",
      "line": 109,
      "relation": "negativeCorrelation",
      "source": 23,
      "target": 71
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "BDNF-mediated ERK1/2 activation through the TrkB receptor is decreased in mutant Htt striatal cells and the reduction is associated with reduced survival. The alteration in signaling appears to be in part due to reduced expression of p52/p46 Sch docking proteins [9].",
      "key": "eabaa1307aa1cdfe428a2a220a9c2b60",
      "line": 94,
      "relation": "increases",
      "source": 37,
      "target": 22
    },
    {
      "key": "a61af6d8d821f5f4c76c9e1db99bced2",
      "relation": "partOf",
      "source": 39,
      "target": 37
    },
    {
      "key": "0c34c3a418fdd157598ec577bdee9a6b",
      "relation": "partOf",
      "source": 66,
      "target": 37
    },
    {
      "annotations": {
        "Anatomy": {
          "striatum": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "BDNF-mediated ERK1/2 activation through the TrkB receptor is decreased in mutant Htt striatal cells and the reduction is associated with reduced survival. The alteration in signaling appears to be in part due to reduced expression of p52/p46 Sch docking proteins [9].",
      "key": "0821258f4be24a0a05e912f1665da42f",
      "line": 98,
      "relation": "increases",
      "source": 22,
      "target": 30
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "BDNF-mediated ERK1/2 activation through the TrkB receptor is decreased in mutant Htt striatal cells and the reduction is associated with reduced survival. The alteration in signaling appears to be in part due to reduced expression of p52/p46 Sch docking proteins [9].",
      "key": "9565c4fd18658cd7079ed5c083d4a43e",
      "line": 102,
      "relation": "positiveCorrelation",
      "source": 22,
      "target": 64
    },
    {
      "annotations": {
        "Anatomy": {
          "striatum": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "BDNF-mediated ERK1/2 activation through the TrkB receptor is decreased in mutant Htt striatal cells and the reduction is associated with reduced survival. The alteration in signaling appears to be in part due to reduced expression of p52/p46 Sch docking proteins [9].",
      "key": "374d11897da3432ac592c20d3be1edb1",
      "line": 97,
      "relation": "decreases",
      "source": 55,
      "target": 22
    },
    {
      "annotations": {
        "Anatomy": {
          "striatum": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "BDNF-mediated ERK1/2 activation through the TrkB receptor is decreased in mutant Htt striatal cells and the reduction is associated with reduced survival. The alteration in signaling appears to be in part due to reduced expression of p52/p46 Sch docking proteins [9].",
      "key": "bb36c34f9b962499dd32a37fd6e40500",
      "line": 99,
      "relation": "decreases",
      "source": 55,
      "target": 30
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "BDNF-mediated ERK1/2 activation through the TrkB receptor is decreased in mutant Htt striatal cells and the reduction is associated with reduced survival. The alteration in signaling appears to be in part due to reduced expression of p52/p46 Sch docking proteins [9].",
      "key": "84dcdd2a99b3140416aec69b95386872",
      "line": 101,
      "relation": "decreases",
      "source": 55,
      "target": 64
    },
    {
      "annotations": {
        "CellLine": {
          "PC-12 cell": true
        },
        "Confidence": {
          "High": true
        },
        "Species": {
          "7215": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "EGFR-induced ERK activation is disrupted in a Drosophila model of HD [10] and ERK activation is impaired after stimulation with EGF or NGF in PC12 cells expressing mutant huntingtin [11].",
      "key": "7b6ca08cc883306ba1a87bd199fb0b1b",
      "line": 111,
      "relation": "decreases",
      "source": 55,
      "target": 23
    },
    {
      "annotations": {
        "Anatomy": {
          "striatum": true
        },
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Huntington's disease": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "In the R6/2 mouse model of HD [21], treatment with pizotifen improved motor function, ameliorated neurodegeneration, restored striatal area, and increased ERK2 activation in the striatum.",
      "key": "78956b4db7674d0888001b1a7d8e6339",
      "line": 137,
      "relation": "decreases",
      "source": 55,
      "target": 23
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Huntington's disease": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "In the R6/2 mouse model of HD [21], treatment with pizotifen improved motor function, ameliorated neurodegeneration, restored striatal area, and increased ERK2 activation in the striatum.",
      "key": "22d71857dc4589231c64c387d0b31b83",
      "line": 130,
      "relation": "decreases",
      "source": 55,
      "target": 27
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Huntington's disease": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "In the R6/2 mouse model of HD [21], treatment with pizotifen improved motor function, ameliorated neurodegeneration, restored striatal area, and increased ERK2 activation in the striatum.",
      "key": "fd94e3ace710e60de5b751fc29f86481",
      "line": 132,
      "relation": "increases",
      "source": 55,
      "target": 70
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Huntington's disease": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "In the R6/2 mouse model of HD [21], treatment with pizotifen improved motor function, ameliorated neurodegeneration, restored striatal area, and increased ERK2 activation in the striatum.",
      "key": "c7d211e7eb9c9bcb67b333c3585da270",
      "line": 134,
      "relation": "increases",
      "source": 55,
      "target": 74
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "Mutant Htt causes the down-regulation of the dopamine- and cAMP-regulated 32-kDa phosphoprotein DARPP-32. DARPP-32 is involved in dopamine and serotonin signaling, is highly expressed in the striatum and prefrontal cortex and is a marker of neuronal dysfunction in HD mice [35,36].",
      "key": "277d6dc008d0e27a638ae9a7a732e747",
      "line": 296,
      "relation": "decreases",
      "source": 55,
      "target": 67
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "BDNF-mediated ERK1/2 activation through the TrkB receptor is decreased in mutant Htt striatal cells and the reduction is associated with reduced survival. The alteration in signaling appears to be in part due to reduced expression of p52/p46 Sch docking proteins [9].",
      "key": "408b0770775d208bade775b57d61e6c6",
      "line": 102,
      "relation": "positiveCorrelation",
      "source": 64,
      "target": 22
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "EGFR-induced ERK activation is disrupted in a Drosophila model of HD [10] and ERK activation is impaired after stimulation with EGF or NGF in PC12 cells expressing mutant huntingtin [11].",
      "key": "a0f47b044d54c2948fb00d89eaa5a225",
      "line": 107,
      "relation": "increases",
      "source": 44,
      "target": 23
    },
    {
      "annotations": {
        "CellLine": {
          "PC-12 cell": true
        },
        "Confidence": {
          "High": true
        },
        "Species": {
          "7215": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "EGFR-induced ERK activation is disrupted in a Drosophila model of HD [10] and ERK activation is impaired after stimulation with EGF or NGF in PC12 cells expressing mutant huntingtin [11].",
      "key": "8b00621b6e2487023630cd6355999fc3",
      "line": 112,
      "relation": "increases",
      "source": 43,
      "target": 23
    },
    {
      "annotations": {
        "CellLine": {
          "PC-12 cell": true
        },
        "Confidence": {
          "High": true
        },
        "Species": {
          "7215": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "EGFR-induced ERK activation is disrupted in a Drosophila model of HD [10] and ERK activation is impaired after stimulation with EGF or NGF in PC12 cells expressing mutant huntingtin [11].",
      "key": "2140b8d3448ad4343cc8626990ae9e60",
      "line": 113,
      "relation": "increases",
      "source": 65,
      "target": 23
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Huntington's disease": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "Examination of down-stream signaling events in ST Hdh Q111/Q111 cells treated with pizotifen showed that rescue of viability in these cells is dependent on transient activation of ERK1/2.",
      "key": "566db3353ad2987b1b1e0b8ac59eef46",
      "line": 122,
      "relation": "increases",
      "source": 15,
      "target": 30
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "Addition of pizotifen, cyproheptadine, or loxapine to the ST Hdh Q7/Q7 cells after serum withdrawal had no effect on ATP levels, indicating that the drugs do not have a general effect on viability but rather correct a deficit specific to the ST Hdh Q111/Q111 cells (Figure 2 A ).",
      "key": "da8aff16144d1dfa53dba3207af4646e",
      "line": 170,
      "relation": "causesNoChange",
      "source": 15,
      "target": 30
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Huntington's disease": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "Examination of down-stream signaling events in ST Hdh Q111/Q111 cells treated with pizotifen showed that rescue of viability in these cells is dependent on transient activation of ERK1/2.",
      "key": "624b3d18b8876e7fefe362ab4a1e9533",
      "line": 123,
      "relation": "increases",
      "source": 15,
      "target": 23
    },
    {
      "annotations": {
        "Anatomy": {
          "striatum": true
        },
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Huntington's disease": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "In the R6/2 mouse model of HD [21], treatment with pizotifen improved motor function, ameliorated neurodegeneration, restored striatal area, and increased ERK2 activation in the striatum.",
      "key": "779e44ce690900ac1c3d64d7f48cc889",
      "line": 138,
      "relation": "increases",
      "source": 15,
      "target": 23
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Huntington's disease": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "In the R6/2 mouse model of HD [21], treatment with pizotifen improved motor function, ameliorated neurodegeneration, restored striatal area, and increased ERK2 activation in the striatum.",
      "key": "3e8dea5485964de346cd82e66485326e",
      "line": 131,
      "relation": "increases",
      "source": 15,
      "target": 27
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Huntington's disease": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "To evaluate potential therapeutic effects of pizotifen treatment in vivo , we measured motor function in HD transgenic R6/2 mice after treatment. Pizotifen (7.5 mg/kg or 10mg/kg) or saline was administered by daily IP injection starting at 6 weeks of age...The lack of effect on open-field behavior suggests that the improved rotarod performance is not simply due to acute effects on activity levels but instead to improved motor coordination.",
      "key": "da0dc67df139428992a523862eb4d8ca",
      "line": 287,
      "relation": "increases",
      "source": 15,
      "target": 27
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Huntington's disease": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "Taken together, results demonstrating that pizotifen can partially normalize levels of DARPP-32 while increasing striatal area indicate that the correction of motor deficits in the R6/2 mouse by pizotifen is likely due to neuroprotective effects of the drug.",
      "key": "c60fb0769d10a530103562620ebd1ab4",
      "line": 390,
      "relation": "increases",
      "source": 15,
      "target": 27
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Huntington's disease": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "These results show that pizotifen can activate striatal ERK1/2 in vitro and in vivo, suggesting that the motor and neuropathological improvements observed in the R6/2 mouse may be mechanistically related to the rescue observed in the cell model.",
      "key": "29f9028e0784936acb49e85baa06971b",
      "line": 450,
      "relation": "increases",
      "source": 15,
      "target": 27
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Huntington's disease": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "In the R6/2 mouse model of HD [21], treatment with pizotifen improved motor function, ameliorated neurodegeneration, restored striatal area, and increased ERK2 activation in the striatum.",
      "key": "bb02c527f8003b0616b2b3aed9e3079a",
      "line": 133,
      "relation": "decreases",
      "source": 15,
      "target": 70
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Huntington's disease": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "In the R6/2 mouse model of HD [21], treatment with pizotifen improved motor function, ameliorated neurodegeneration, restored striatal area, and increased ERK2 activation in the striatum.",
      "key": "b60bbef35c22804b8788d4ce92682371",
      "line": 135,
      "relation": "decreases",
      "source": 15,
      "target": 74
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "As shown in Figure 1 B , these drugs restored ATP levels in ST Hdh Q111/Q111 cells after serum withdrawal in a dose-dependent manner.",
      "key": "3cc07316d7fd861866b2c049d1649608",
      "line": 148,
      "relation": "increases",
      "source": 15,
      "target": 1
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "Addition of pizotifen, cyproheptadine, or loxapine to the ST Hdh Q7/Q7 cells after serum withdrawal had no effect on ATP levels, indicating that the drugs do not have a general effect on viability but rather correct a deficit specific to the ST Hdh Q111/Q111 cells (Figure 2 A ).",
      "key": "1487924f5d3bd6aef882aaefa271a553",
      "line": 167,
      "relation": "causesNoChange",
      "source": 15,
      "target": 1
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": " Caspase activation in the ST Hdh Q111/Q111 cells was significantly blocked by the addition of the pizotifen, cyproheptadine, or loxapine in a dose-dependent manner (Figure 1 D , compound structures 1E).",
      "key": "ca55438589d4c0d80ac1d0d9ad6f2f7a",
      "line": 156,
      "relation": "decreases",
      "source": 15,
      "target": 40
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": " Caspase activation in the ST Hdh Q111/Q111 cells was significantly blocked by the addition of the pizotifen, cyproheptadine, or loxapine in a dose-dependent manner (Figure 1 D , compound structures 1E).",
      "key": "6b7d0428090edc03c3fb822ec3c1282a",
      "line": 159,
      "relation": "decreases",
      "source": 15,
      "target": 41
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "A significant increase in the phosphorylation of ERK1 (p44) occurred after a 15-min treatment with pizotifen, cyproheptadine, or loxapine in both ST Hdh Q111/Q111 and ST Hdh Q7/Q7 cells (Figure 3 A ).",
      "key": "a92824662d1582ac85c3c07b62e9b812",
      "line": 178,
      "relation": "increases",
      "source": 15,
      "target": 63
    },
    {
      "annotations": {
        "Anatomy": {
          "cortex": true
        },
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Huntington's disease": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "Interestingly, western blotting analysis showed that the levels of phospho-ERK1 (p44) are significantly reduced in the cortex of the HD transgenic R6/2 mice at 10 weeks of age with pizotifen treatment (Figure 10 B ).",
      "key": "f3b5e9611a6434e590ff4b2f8a00e547",
      "line": 426,
      "relation": "decreases",
      "source": 15,
      "target": 63
    },
    {
      "annotations": {
        "Anatomy": {
          "prefrontal cortex": true,
          "striatum": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "The lower levels of phospho-ERK1 (p44) in the cortex may reflect distinct signaling pathways in these two regions of the brain in response to pizotifen.",
      "key": "482220a1b26f2ba58190169d8002e83e",
      "line": 459,
      "relation": "decreases",
      "source": 15,
      "target": 63
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": " A significant increase in phospho-ERK2 (p42) occurred after treatment with pizotifen and loxapine and an upward trend occurred after treatment with cyproheptadine in ST Hdh Q111/Q111cells. Pizotifen treatment significantly increased phospho-ERK2 in ST Hdh Q7/Q7 cells (Figure 3B).",
      "key": "8d74f081e07bf5faacbb3ab5566fd35b",
      "line": 186,
      "relation": "increases",
      "source": 15,
      "target": 60
    },
    {
      "annotations": {
        "Anatomy": {
          "striatum": true
        },
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Huntington's disease": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "At 10 weeks of age, we observed that levels of activated ERK2 (p42) were increased in the striatum of the pizotifen-treated HD transgenic R6/2 mice both by IHC and western blotting (Figure 10 A, C).",
      "key": "dd79f0950e107799e35784e2629016ba",
      "line": 413,
      "relation": "increases",
      "source": 15,
      "target": 60
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "We measured the time-course of pizotifen-induced ERK activation under conditions of serum withdrawal in ST Hdh Q111/Q111 cells and found significant increases in phosphoERK1/2 after five and fifteen minutes of treatment (Figure 3 C,D).",
      "key": "2a62d5fd49191b44d5b7a07b3167b3d9",
      "line": 197,
      "relation": "increases",
      "source": 15,
      "target": 62
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "PhosphoERK1/2 levels in DMSO control cells increased slowly with time and were approximately equal between pizotifen and control cells after 24 hours of treatment.",
      "key": "376be78577780ae44e9cce336cceda4e",
      "line": 204,
      "relation": "increases",
      "source": 15,
      "target": 62
    },
    {
      "annotations": {
        "Anatomy": {
          "striatum": true
        },
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Huntington's disease": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "These results show that pizotifen can activate striatal ERK1/2 in vitro and in vivo, suggesting that the motor and neuropathological improvements observed in the R6/2 mouse may be mechanistically related to the rescue observed in the cell model.",
      "key": "ada3ab41c2e573d907cafec3fcd2d7ef",
      "line": 446,
      "relation": "increases",
      "source": 15,
      "target": 62
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "We measured the time-course of pizotifen-induced ERK activation under conditions of serum withdrawal in ST Hdh Q111/Q111 cells and found significant increases in phosphoERK1/2 after five and fifteen minutes of treatment (Figure 3 C,D).",
      "key": "08e2efdec079ad3fd1e7dacc6dc0573c",
      "line": 198,
      "relation": "increases",
      "source": 15,
      "target": 59
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "PhosphoERK1/2 levels in DMSO control cells increased slowly with time and were approximately equal between pizotifen and control cells after 24 hours of treatment.",
      "key": "4870f377530d46c3defc11f8d626da87",
      "line": 205,
      "relation": "increases",
      "source": 15,
      "target": 59
    },
    {
      "annotations": {
        "Anatomy": {
          "striatum": true
        },
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Huntington's disease": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "These results show that pizotifen can activate striatal ERK1/2 in vitro and in vivo, suggesting that the motor and neuropathological improvements observed in the R6/2 mouse may be mechanistically related to the rescue observed in the cell model.",
      "key": "0c46223fc3bf7b4e967dc94da7f5046e",
      "line": 447,
      "relation": "increases",
      "source": 15,
      "target": 59
    },
    {
      "key": "c2b04da24e2e822bec6597961aa1c8c7",
      "relation": "partOf",
      "source": 15,
      "target": 38
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "Pizotifen is a serotonin antagonist used to treat recurrent migraine [22]. It binds to over 30 receptors, including subtypes of the serotonin, dopamine, histamine, adrenoreceptor, and cholinergic receptors (for binding profile, see Young et. al. [19])",
      "key": "616e8e1c98ac82c24a41856037be19bf",
      "line": 227,
      "relation": "decreases",
      "source": 15,
      "target": 18
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "Pizotifen is a serotonin antagonist used to treat recurrent migraine [22]. It binds to over 30 receptors, including subtypes of the serotonin, dopamine, histamine, adrenoreceptor, and cholinergic receptors (for binding profile, see Young et. al. [19])",
      "key": "fd9f5fecca2c5ce83efb00c2dbb1570d",
      "line": 228,
      "relation": "decreases",
      "source": 15,
      "target": 72
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "In addition, pizotifen has been shown to be a partial agonist of the 5-HT1A receptor. Agonism was reportedly blocked by the 5-HT1A antagonist WAY-100,635 [23]. WAY-100,635 also blocks the activation of ERK by several antipsychotic drugs that are agonists of the 5-HT1A receptor, as well as the activation of ERK through the 5-HT1A endogenous ligand serotonin [24].",
      "key": "15ce4ddea30d4de8c38404c4c44ee0c4",
      "line": 233,
      "relation": "increases",
      "source": 15,
      "target": 52
    },
    {
      "annotations": {
        "Anatomy": {
          "striatum": true
        },
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "By immunohistochemistry (IHC), we found that levels of DARPP-32 in the striatum of the HD transgenic R6/2 mice were reduced at 10 weeks of age qualitatively. Pizotifen treatment increased DARPP-32 staining in the striatum at this time point (Figure 8 A ).",
      "key": "6f79db0f20b0574a3afa0f7bd3469d19",
      "line": 313,
      "relation": "increases",
      "source": 15,
      "target": 67
    },
    {
      "annotations": {
        "Anatomy": {
          "striatum": true
        },
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Huntington's disease": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "At 12-weeks of age, the pizotifen treatment resulted in a statistically significant increase in striatal DARPP-32 levels when compared to untreated R6/2 controls (Figure 8C).",
      "key": "483d01e94dd7e3dd0648a8ac7e3b5c3a",
      "line": 325,
      "relation": "increases",
      "source": 15,
      "target": 67
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Huntington's disease": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "Taken together, results demonstrating that pizotifen can partially normalize levels of DARPP-32 while increasing striatal area indicate that the correction of motor deficits in the R6/2 mouse by pizotifen is likely due to neuroprotective effects of the drug.",
      "key": "f119ae4a202e679cba6b0b11231b753c",
      "line": 386,
      "relation": "increases",
      "source": 15,
      "target": 67
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "The levels of mGluR2/3 in HD transgenic R6/2 mice at 10 weeks of age were slightly reduced and pizotifen treatment modestly increased levels of this receptor.",
      "key": "23f420e8cfea84d659e747ffd036dfec",
      "line": 349,
      "relation": "increases",
      "source": 15,
      "target": 49
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "The levels of mGluR2/3 in HD transgenic R6/2 mice at 10 weeks of age were slightly reduced and pizotifen treatment modestly increased levels of this receptor.",
      "key": "bb7616b6bab8bb68bc0d8ed4d86cda2f",
      "line": 350,
      "relation": "increases",
      "source": 15,
      "target": 50
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "D2DR, GAD65/67 and 5HT1B levels are also altered in the HD transgenic R6/2 mice, but pizotifen treatment did not normalize the levels (data not shown).",
      "key": "f747dd90a4a6cde7a061a73ce998b4c3",
      "line": 362,
      "relation": "causesNoChange",
      "source": 15,
      "target": 42
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "D2DR, GAD65/67 and 5HT1B levels are also altered in the HD transgenic R6/2 mice, but pizotifen treatment did not normalize the levels (data not shown).",
      "key": "1019201b8778e302063dd0a671645988",
      "line": 363,
      "relation": "causesNoChange",
      "source": 15,
      "target": 46
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "D2DR, GAD65/67 and 5HT1B levels are also altered in the HD transgenic R6/2 mice, but pizotifen treatment did not normalize the levels (data not shown).",
      "key": "6e718dec42f5a702e2081644091efd45",
      "line": 364,
      "relation": "causesNoChange",
      "source": 15,
      "target": 45
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "D2DR, GAD65/67 and 5HT1B levels are also altered in the HD transgenic R6/2 mice, but pizotifen treatment did not normalize the levels (data not shown).",
      "key": "0bb4fe27f7563c121d7a96c58fab7cac",
      "line": 365,
      "relation": "causesNoChange",
      "source": 15,
      "target": 53
    },
    {
      "annotations": {
        "Anatomy": {
          "striatum": true
        },
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "We confirmed that the striatal area was reduced in the striatum of the HD transgenic R6/2 mice at 10 weeks of age and found that pizotifen treatment attenuated this reduction in striatal area (Figure 8 D ).",
      "key": "e77f5afc3e02a0bf33ca6b898012dddb",
      "line": 376,
      "relation": "decreases",
      "source": 15,
      "target": 28
    },
    {
      "annotations": {
        "Anatomy": {
          "striatum": true
        },
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Huntington's disease": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "Taken together, results demonstrating that pizotifen can partially normalize levels of DARPP-32 while increasing striatal area indicate that the correction of motor deficits in the R6/2 mouse by pizotifen is likely due to neuroprotective effects of the drug.",
      "key": "ba48f4f55b132d46d8ad540a2b47c305",
      "line": 388,
      "relation": "decreases",
      "source": 15,
      "target": 28
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Huntington's disease": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "Taken together, results demonstrating that pizotifen can partially normalize levels of DARPP-32 while increasing striatal area indicate that the correction of motor deficits in the R6/2 mouse by pizotifen is likely due to neuroprotective effects of the drug.",
      "key": "a5cf39b4063da9a9092adc2a6b8b5f4c",
      "line": 391,
      "relation": "isA",
      "source": 15,
      "target": 3
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Huntington's disease": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "We did not detect any changes in the levels of Htt protein or localization in the R6/2 mouse model suggesting that the mechanism is not mediated through clearance pathways (Figure 9, and data not shown).",
      "key": "2965591a8657ec808b43ba56abf63ab8",
      "line": 401,
      "relation": "causesNoChange",
      "source": 15,
      "target": 54
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Huntington's disease": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "These results show that pizotifen can activate striatal ERK1/2 in vitro and in vivo, suggesting that the motor and neuropathological improvements observed in the R6/2 mouse may be mechanistically related to the rescue observed in the cell model.",
      "key": "06e9df020c8b317ac97eea91d68f2576",
      "line": 451,
      "relation": "decreases",
      "source": 15,
      "target": 75
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "As shown in Figure 1 B , these drugs restored ATP levels in ST Hdh Q111/Q111 cells after serum withdrawal in a dose-dependent manner.",
      "key": "8520c9f450b6405dacf7fb56ebf8d4ff",
      "line": 149,
      "relation": "increases",
      "source": 6,
      "target": 1
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "Addition of pizotifen, cyproheptadine, or loxapine to the ST Hdh Q7/Q7 cells after serum withdrawal had no effect on ATP levels, indicating that the drugs do not have a general effect on viability but rather correct a deficit specific to the ST Hdh Q111/Q111 cells (Figure 2 A ).",
      "key": "6f5bd1c66dfe3abe583b992688b45e15",
      "line": 168,
      "relation": "causesNoChange",
      "source": 6,
      "target": 1
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": " Caspase activation in the ST Hdh Q111/Q111 cells was significantly blocked by the addition of the pizotifen, cyproheptadine, or loxapine in a dose-dependent manner (Figure 1 D , compound structures 1E).",
      "key": "89c1862dc38037a1f84fbcffcc37295e",
      "line": 157,
      "relation": "decreases",
      "source": 6,
      "target": 40
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": " Caspase activation in the ST Hdh Q111/Q111 cells was significantly blocked by the addition of the pizotifen, cyproheptadine, or loxapine in a dose-dependent manner (Figure 1 D , compound structures 1E).",
      "key": "2b1547823b2ea8641dd8b0e3c02e0f1b",
      "line": 160,
      "relation": "decreases",
      "source": 6,
      "target": 41
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "Addition of pizotifen, cyproheptadine, or loxapine to the ST Hdh Q7/Q7 cells after serum withdrawal had no effect on ATP levels, indicating that the drugs do not have a general effect on viability but rather correct a deficit specific to the ST Hdh Q111/Q111 cells (Figure 2 A ).",
      "key": "5dc8236435e3fbd690750c5e2b8c29fb",
      "line": 171,
      "relation": "causesNoChange",
      "source": 6,
      "target": 30
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "A significant increase in the phosphorylation of ERK1 (p44) occurred after a 15-min treatment with pizotifen, cyproheptadine, or loxapine in both ST Hdh Q111/Q111 and ST Hdh Q7/Q7 cells (Figure 3 A ).",
      "key": "d0101b2f7bdec6b2185c1e96e9d90e5f",
      "line": 179,
      "relation": "increases",
      "source": 6,
      "target": 63
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": " A significant increase in phospho-ERK2 (p42) occurred after treatment with pizotifen and loxapine and an upward trend occurred after treatment with cyproheptadine in ST Hdh Q111/Q111cells. Pizotifen treatment significantly increased phospho-ERK2 in ST Hdh Q7/Q7 cells (Figure 3B).",
      "key": "ef2eb2beea14250f5f9a6afc2578acfa",
      "line": 187,
      "relation": "increases",
      "source": 6,
      "target": 60
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "As shown in Figure 1 B , these drugs restored ATP levels in ST Hdh Q111/Q111 cells after serum withdrawal in a dose-dependent manner.",
      "key": "b4fba8a84140063dbec7f23d5affe3a8",
      "line": 150,
      "relation": "increases",
      "source": 13,
      "target": 1
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "Addition of pizotifen, cyproheptadine, or loxapine to the ST Hdh Q7/Q7 cells after serum withdrawal had no effect on ATP levels, indicating that the drugs do not have a general effect on viability but rather correct a deficit specific to the ST Hdh Q111/Q111 cells (Figure 2 A ).",
      "key": "5a14cfb7fd22fdd688a2bab90640741c",
      "line": 169,
      "relation": "causesNoChange",
      "source": 13,
      "target": 1
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": " Caspase activation in the ST Hdh Q111/Q111 cells was significantly blocked by the addition of the pizotifen, cyproheptadine, or loxapine in a dose-dependent manner (Figure 1 D , compound structures 1E).",
      "key": "f02fa1a3ba2822ba6389de7cf9ddf912",
      "line": 158,
      "relation": "decreases",
      "source": 13,
      "target": 40
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "Addition of pizotifen, cyproheptadine, or loxapine to the ST Hdh Q7/Q7 cells after serum withdrawal had no effect on ATP levels, indicating that the drugs do not have a general effect on viability but rather correct a deficit specific to the ST Hdh Q111/Q111 cells (Figure 2 A ).",
      "key": "cbe97b661f913aa114b805b32edbbe10",
      "line": 172,
      "relation": "causesNoChange",
      "source": 13,
      "target": 30
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "A significant increase in the phosphorylation of ERK1 (p44) occurred after a 15-min treatment with pizotifen, cyproheptadine, or loxapine in both ST Hdh Q111/Q111 and ST Hdh Q7/Q7 cells (Figure 3 A ).",
      "key": "acc541837f90d283905629c119415bc9",
      "line": 180,
      "relation": "increases",
      "source": 13,
      "target": 63
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": " A significant increase in phospho-ERK2 (p42) occurred after treatment with pizotifen and loxapine and an upward trend occurred after treatment with cyproheptadine in ST Hdh Q111/Q111cells. Pizotifen treatment significantly increased phospho-ERK2 in ST Hdh Q7/Q7 cells (Figure 3B).",
      "key": "eb9257d95187ab43ab5ae20b6597ff28",
      "line": 188,
      "relation": "increases",
      "source": 13,
      "target": 60
    },
    {
      "annotations": {
        "Cell": {
          "neuron": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "The activated ERK by IHC was demonstrated by an increased number of neurons staining positive for phospho-ERK qualitatively (Figure 10C).",
      "key": "725f95b372c98fe6e5db4e872a41b4f5",
      "line": 435,
      "relation": "increases",
      "source": 63,
      "target": 23
    },
    {
      "key": "7563f8a57169fb8a290d4e5c39b38e37",
      "relation": "hasVariant",
      "source": 61,
      "target": 63
    },
    {
      "key": "ab63e9625f84179d19f6f8c3cfc7c14d",
      "relation": "hasVariant",
      "source": 61,
      "target": 62
    },
    {
      "annotations": {
        "Cell": {
          "neuron": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "The activated ERK by IHC was demonstrated by an increased number of neurons staining positive for phospho-ERK qualitatively (Figure 10C).",
      "key": "4bb69710e4c8d20442782ae8ffe374f3",
      "line": 436,
      "relation": "increases",
      "source": 60,
      "target": 23
    },
    {
      "key": "0f4889995bf6db41d1aa7ea66522aba4",
      "relation": "hasVariant",
      "source": 58,
      "target": 60
    },
    {
      "key": "5b2f5e36b6fb00f68558b79b66f7e7e7",
      "relation": "hasVariant",
      "source": 58,
      "target": 59
    },
    {
      "key": "11b871a8fcc8faf868c696ac01497f30",
      "relation": "partOf",
      "source": 62,
      "target": 38
    },
    {
      "key": "4ab12e6ed89e6d0e94f62e4b984e3f24",
      "relation": "partOf",
      "source": 59,
      "target": 38
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "PhosphoERK1/2 levels in DMSO control cells increased slowly with time and were approximately equal between pizotifen and control cells after 24 hours of treatment.",
      "key": "277b4a3f425ec85d15c3b980e1f4be51",
      "line": 207,
      "relation": "increases",
      "source": 2,
      "target": 62
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "PhosphoERK1/2 levels in DMSO control cells increased slowly with time and were approximately equal between pizotifen and control cells after 24 hours of treatment.",
      "key": "b5ceba78a87d1c1f9e3c313face59bf8",
      "line": 208,
      "relation": "increases",
      "source": 2,
      "target": 59
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "To determine if transient pizotifen-induced ERK phosphorylation is necessary for rescue of mutant Htt toxicity, we blocked ERK phosphorylation by co-treatment with MEK1/2 inhibitor U0126.",
      "key": "5c9cf745f35178676c796d7f448119fc",
      "line": 213,
      "relation": "decreases",
      "source": 4,
      "target": 56
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "To determine if transient pizotifen-induced ERK phosphorylation is necessary for rescue of mutant Htt toxicity, we blocked ERK phosphorylation by co-treatment with MEK1/2 inhibitor U0126.",
      "key": "5975a171d33292dde5aba51ff6d26b10",
      "line": 214,
      "relation": "decreases",
      "source": 4,
      "target": 57
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "To determine if transient pizotifen-induced ERK phosphorylation is necessary for rescue of mutant Htt toxicity, we blocked ERK phosphorylation by co-treatment with MEK1/2 inhibitor U0126.",
      "key": "e89bcb73fa09c614eedc73ac09bd59e2",
      "line": 215,
      "relation": "decreases",
      "source": 4,
      "target": 62
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "To determine if transient pizotifen-induced ERK phosphorylation is necessary for rescue of mutant Htt toxicity, we blocked ERK phosphorylation by co-treatment with MEK1/2 inhibitor U0126.",
      "key": "54490f99c5a2f6e94bb59b0f59a0380e",
      "line": 216,
      "relation": "decreases",
      "source": 4,
      "target": 59
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "Inhibiting ERK1/2 phosphorylation in the presence of pizotifen prevented the rescue of ST Hdh Q111/Q111 cells in the ATP assay (Figure 4 C ).",
      "key": "3c721e6bc5f74b4544c2bf8d2b9a2aa0",
      "line": 222,
      "relation": "increases",
      "source": 38,
      "target": 30
    },
    {
      "key": "d3cdcdb7f9d5ab1eacf11f1b7a9242a3",
      "relation": "partOf",
      "source": 18,
      "target": 35
    },
    {
      "key": "34ae09964db1383db32b6d9a23d2417f",
      "relation": "partOf",
      "source": 52,
      "target": 35
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "In addition, pizotifen has been shown to be a partial agonist of the 5-HT1A receptor. Agonism was reportedly blocked by the 5-HT1A antagonist WAY-100,635 [23]. WAY-100,635 also blocks the activation of ERK by several antipsychotic drugs that are agonists of the 5-HT1A receptor, as well as the activation of ERK through the 5-HT1A endogenous ligand serotonin [24].",
      "key": "af5a273f3bd751808936026db85dfcb7",
      "line": 234,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 21,
      "target": 15
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "In addition, pizotifen has been shown to be a partial agonist of the 5-HT1A receptor. Agonism was reportedly blocked by the 5-HT1A antagonist WAY-100,635 [23]. WAY-100,635 also blocks the activation of ERK by several antipsychotic drugs that are agonists of the 5-HT1A receptor, as well as the activation of ERK through the 5-HT1A endogenous ligand serotonin [24].",
      "key": "5a1f9a202d5fb0a19d5e6b6f97fb28cb",
      "line": 235,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 21,
      "target": 61
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "In addition, pizotifen has been shown to be a partial agonist of the 5-HT1A receptor. Agonism was reportedly blocked by the 5-HT1A antagonist WAY-100,635 [23]. WAY-100,635 also blocks the activation of ERK by several antipsychotic drugs that are agonists of the 5-HT1A receptor, as well as the activation of ERK through the 5-HT1A endogenous ligand serotonin [24].",
      "key": "a498281907a59d32afcfaf5b9c4dc21f",
      "line": 236,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 21,
      "target": 58
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "In addition, pizotifen has been shown to be a partial agonist of the 5-HT1A receptor. Agonism was reportedly blocked by the 5-HT1A antagonist WAY-100,635 [23]. WAY-100,635 also blocks the activation of ERK by several antipsychotic drugs that are agonists of the 5-HT1A receptor, as well as the activation of ERK through the 5-HT1A endogenous ligand serotonin [24].",
      "key": "03d994265165ca72dec9b9aef704ed90",
      "line": 237,
      "relation": "increases",
      "source": 21,
      "target": 35
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "In addition, pizotifen has been shown to be a partial agonist of the 5-HT1A receptor. Agonism was reportedly blocked by the 5-HT1A antagonist WAY-100,635 [23]. WAY-100,635 also blocks the activation of ERK by several antipsychotic drugs that are agonists of the 5-HT1A receptor, as well as the activation of ERK through the 5-HT1A endogenous ligand serotonin [24].",
      "key": "2338cfe0526a788f01dd63bdb8c29dcb",
      "line": 238,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 35,
      "target": 61
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "In addition, pizotifen has been shown to be a partial agonist of the 5-HT1A receptor. Agonism was reportedly blocked by the 5-HT1A antagonist WAY-100,635 [23]. WAY-100,635 also blocks the activation of ERK by several antipsychotic drugs that are agonists of the 5-HT1A receptor, as well as the activation of ERK through the 5-HT1A endogenous ligand serotonin [24].",
      "key": "c38473a1287734103d539cf7d44b569c",
      "line": 239,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 35,
      "target": 58
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "Another 5-HT1A antagonist, NAD-299, exhibits a pharmacological profile similar to WAY-100,635 [25], with both WAY-100,635 and NAD-299 showing high selectivity for the 5-HT1A receptor (binding it with nanomolar affinities).",
      "key": "366b538910fecf824d6bdf186a8e0f7e",
      "line": 245,
      "relation": "decreases",
      "source": 20,
      "target": 52
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "To determine if we had overlooked other active compounds from the Prestwick library, we retested risperidone, metergoline, ketanserin, spiperone, and promethazine. These drugs have overlapping targets with pizotifen and are known to act through serotonin receptors [20, 27, 28, 29, 30, 31, 32, 33].",
      "key": "87bc20638a77604bfa7161919f00bc0c",
      "line": 250,
      "object": {
        "effect": {
          "name": "serotonin receptor activity",
          "namespace": "GO"
        },
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 34,
      "target": 17
    },
    {
      "key": "a5cbe8463d496f1dfa207a8a97849921",
      "relation": "partOf",
      "source": 17,
      "target": 34
    },
    {
      "key": "901c1d5e5546f8832cd617c6735d3e95",
      "relation": "partOf",
      "source": 68,
      "target": 34
    },
    {
      "key": "c459de119bae2d55e9334c99ab73aff4",
      "relation": "partOf",
      "source": 68,
      "target": 32
    },
    {
      "key": "974425ec1fbe95a9c76547e7b852584c",
      "relation": "partOf",
      "source": 68,
      "target": 31
    },
    {
      "key": "b030dc1a1df50838d252e5640f5a914b",
      "relation": "partOf",
      "source": 68,
      "target": 36
    },
    {
      "key": "c06cf70784b8115026e950c57f7532e0",
      "relation": "partOf",
      "source": 68,
      "target": 33
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "To determine if we had overlooked other active compounds from the Prestwick library, we retested risperidone, metergoline, ketanserin, spiperone, and promethazine. These drugs have overlapping targets with pizotifen and are known to act through serotonin receptors [20, 27, 28, 29, 30, 31, 32, 33].",
      "key": "74399ccccb5e6cde79d477def9aa7808",
      "line": 251,
      "object": {
        "effect": {
          "name": "serotonin receptor activity",
          "namespace": "GO"
        },
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 32,
      "target": 14
    },
    {
      "key": "b11b619e990daa1e386389e4c5d58f12",
      "relation": "partOf",
      "source": 14,
      "target": 32
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "To determine if we had overlooked other active compounds from the Prestwick library, we retested risperidone, metergoline, ketanserin, spiperone, and promethazine. These drugs have overlapping targets with pizotifen and are known to act through serotonin receptors [20, 27, 28, 29, 30, 31, 32, 33].",
      "key": "52567930d910641cb0e1821c2e9e7d75",
      "line": 252,
      "object": {
        "effect": {
          "name": "serotonin receptor activity",
          "namespace": "GO"
        },
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 31,
      "target": 10
    },
    {
      "key": "04ea8ddad62a9f531d2d42bf9e289946",
      "relation": "partOf",
      "source": 10,
      "target": 31
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "To determine if we had overlooked other active compounds from the Prestwick library, we retested risperidone, metergoline, ketanserin, spiperone, and promethazine. These drugs have overlapping targets with pizotifen and are known to act through serotonin receptors [20, 27, 28, 29, 30, 31, 32, 33].",
      "key": "02831cfba80ea99fd6c9548804082299",
      "line": 253,
      "object": {
        "effect": {
          "name": "serotonin receptor activity",
          "namespace": "GO"
        },
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 36,
      "target": 19
    },
    {
      "key": "4682e7ed628bb516ce184a20978cf954",
      "relation": "partOf",
      "source": 19,
      "target": 36
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "To determine if we had overlooked other active compounds from the Prestwick library, we retested risperidone, metergoline, ketanserin, spiperone, and promethazine. These drugs have overlapping targets with pizotifen and are known to act through serotonin receptors [20, 27, 28, 29, 30, 31, 32, 33].",
      "key": "f06e853329a64bb365fb6d2ec35b9ff6",
      "line": 254,
      "object": {
        "effect": {
          "name": "serotonin receptor activity",
          "namespace": "GO"
        },
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 33,
      "target": 16
    },
    {
      "key": "d15bc1097142a030d7da997de5fd0b53",
      "relation": "partOf",
      "source": 16,
      "target": 33
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "One drug, promethazine, rescued ST Hdh Q111/Q111 cells (Figure 5). Promethazine is also a high affinity antagonist of the H1 receptor and has previously been reported to rescue an HD model [34].",
      "key": "3890040f71ccce19afb81764456e130a",
      "line": 260,
      "relation": "increases",
      "source": 16,
      "target": 30
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "One drug, promethazine, rescued ST Hdh Q111/Q111 cells (Figure 5). Promethazine is also a high affinity antagonist of the H1 receptor and has previously been reported to rescue an HD model [34].",
      "key": "0f8ec7d8cb1b78f1f085f9329e0e19ea",
      "line": 261,
      "relation": "decreases",
      "source": 16,
      "target": 51
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "One drug, promethazine, rescued ST Hdh Q111/Q111 cells (Figure 5). Promethazine is also a high affinity antagonist of the H1 receptor and has previously been reported to rescue an HD model [34].",
      "key": "0b92fc40e8b1621c38055a997232953a",
      "line": 262,
      "relation": "decreases",
      "source": 16,
      "target": 71
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "Cetirizine, diphenhydramine, ketotifen, desloratadine, and chlorphreniramine failed to rescue ST Hdh Q111/Q111 cells (Figure 6). This suggests that the activity of the drugs in the cell-based assay is not related solely to their common ability to block the H1 receptor.",
      "key": "946463adcb2aa2c902a73329e90f2169",
      "line": 267,
      "relation": "decreases",
      "source": 5,
      "target": 51
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "Cetirizine, diphenhydramine, ketotifen, desloratadine, and chlorphreniramine failed to rescue ST Hdh Q111/Q111 cells (Figure 6). This suggests that the activity of the drugs in the cell-based assay is not related solely to their common ability to block the H1 receptor.",
      "key": "83bfb6249720b6c718ddbb6181d45fe3",
      "line": 273,
      "relation": "causesNoChange",
      "source": 5,
      "target": 30
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "Cetirizine, diphenhydramine, ketotifen, desloratadine, and chlorphreniramine failed to rescue ST Hdh Q111/Q111 cells (Figure 6). This suggests that the activity of the drugs in the cell-based assay is not related solely to their common ability to block the H1 receptor.",
      "key": "6e06c7f66df829ea46b351a9c7a65ebb",
      "line": 268,
      "relation": "decreases",
      "source": 8,
      "target": 51
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "Cetirizine, diphenhydramine, ketotifen, desloratadine, and chlorphreniramine failed to rescue ST Hdh Q111/Q111 cells (Figure 6). This suggests that the activity of the drugs in the cell-based assay is not related solely to their common ability to block the H1 receptor.",
      "key": "137daaef2cab793488ddce5beb18e68c",
      "line": 274,
      "relation": "causesNoChange",
      "source": 8,
      "target": 30
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "Cetirizine, diphenhydramine, ketotifen, desloratadine, and chlorphreniramine failed to rescue ST Hdh Q111/Q111 cells (Figure 6). This suggests that the activity of the drugs in the cell-based assay is not related solely to their common ability to block the H1 receptor.",
      "key": "89d76f0daf11c369719cb818761bd1bc",
      "line": 269,
      "relation": "decreases",
      "source": 11,
      "target": 51
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "Cetirizine, diphenhydramine, ketotifen, desloratadine, and chlorphreniramine failed to rescue ST Hdh Q111/Q111 cells (Figure 6). This suggests that the activity of the drugs in the cell-based assay is not related solely to their common ability to block the H1 receptor.",
      "key": "27b821a2dc5902194de9e39e1457772c",
      "line": 275,
      "relation": "causesNoChange",
      "source": 11,
      "target": 30
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "Cetirizine, diphenhydramine, ketotifen, desloratadine, and chlorphreniramine failed to rescue ST Hdh Q111/Q111 cells (Figure 6). This suggests that the activity of the drugs in the cell-based assay is not related solely to their common ability to block the H1 receptor.",
      "key": "745dd0f73e2c2e1a61e75733358233b0",
      "line": 270,
      "relation": "decreases",
      "source": 7,
      "target": 51
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "Cetirizine, diphenhydramine, ketotifen, desloratadine, and chlorphreniramine failed to rescue ST Hdh Q111/Q111 cells (Figure 6). This suggests that the activity of the drugs in the cell-based assay is not related solely to their common ability to block the H1 receptor.",
      "key": "78ff3c75aad5b1a564fb67421288e7cf",
      "line": 276,
      "relation": "causesNoChange",
      "source": 7,
      "target": 30
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "Cetirizine, diphenhydramine, ketotifen, desloratadine, and chlorphreniramine failed to rescue ST Hdh Q111/Q111 cells (Figure 6). This suggests that the activity of the drugs in the cell-based assay is not related solely to their common ability to block the H1 receptor.",
      "key": "bd8650362ea8642c4a6073f8c1211c89",
      "line": 271,
      "relation": "decreases",
      "source": 12,
      "target": 51
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "Cetirizine, diphenhydramine, ketotifen, desloratadine, and chlorphreniramine failed to rescue ST Hdh Q111/Q111 cells (Figure 6). This suggests that the activity of the drugs in the cell-based assay is not related solely to their common ability to block the H1 receptor.",
      "key": "99a7db06055e9baab56ddcde227c5597",
      "line": 277,
      "relation": "causesNoChange",
      "source": 12,
      "target": 30
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "Mutant Htt causes the down-regulation of the dopamine- and cAMP-regulated 32-kDa phosphoprotein DARPP-32. DARPP-32 is involved in dopamine and serotonin signaling, is highly expressed in the striatum and prefrontal cortex and is a marker of neuronal dysfunction in HD mice [35,36].",
      "key": "b31fd1c5b3d18e459916000ffc0b771e",
      "line": 294,
      "relation": "regulates",
      "source": 0,
      "target": 67
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "Mutant Htt causes the down-regulation of the dopamine- and cAMP-regulated 32-kDa phosphoprotein DARPP-32. DARPP-32 is involved in dopamine and serotonin signaling, is highly expressed in the striatum and prefrontal cortex and is a marker of neuronal dysfunction in HD mice [35,36].",
      "key": "f167ccfcd031d4069a8bbdc7123d981f",
      "line": 297,
      "relation": "association",
      "source": 67,
      "target": 24
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "Mutant Htt causes the down-regulation of the dopamine- and cAMP-regulated 32-kDa phosphoprotein DARPP-32. DARPP-32 is involved in dopamine and serotonin signaling, is highly expressed in the striatum and prefrontal cortex and is a marker of neuronal dysfunction in HD mice [35,36].",
      "key": "eaaeda481a66ae9b960f2765247e9e34",
      "line": 298,
      "relation": "association",
      "source": 67,
      "target": 29
    },
    {
      "annotations": {
        "Anatomy": {
          "prefrontal cortex": true,
          "striatum": true
        },
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "Mutant Htt causes the down-regulation of the dopamine- and cAMP-regulated 32-kDa phosphoprotein DARPP-32. DARPP-32 is involved in dopamine and serotonin signaling, is highly expressed in the striatum and prefrontal cortex and is a marker of neuronal dysfunction in HD mice [35,36].",
      "key": "f46c472cfdd445a55ae57e4a77861f3f",
      "line": 301,
      "relation": "prognosticBiomarkerFor",
      "source": 67,
      "target": 71
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "Mutant Htt causes the down-regulation of the dopamine- and cAMP-regulated 32-kDa phosphoprotein DARPP-32. DARPP-32 is involved in dopamine and serotonin signaling, is highly expressed in the striatum and prefrontal cortex and is a marker of neuronal dysfunction in HD mice [35,36].",
      "key": "76f3c5a6e3c15ad99f43056ab98a89bc",
      "line": 295,
      "relation": "regulates",
      "source": 9,
      "target": 67
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "Mutant Htt causes the down-regulation of the dopamine- and cAMP-regulated 32-kDa phosphoprotein DARPP-32. DARPP-32 is involved in dopamine and serotonin signaling, is highly expressed in the striatum and prefrontal cortex and is a marker of neuronal dysfunction in HD mice [35,36].",
      "key": "59f467f493b601e9ce1945b0f6fca356",
      "line": 297,
      "relation": "association",
      "source": 24,
      "target": 67
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "Mutant Htt causes the down-regulation of the dopamine- and cAMP-regulated 32-kDa phosphoprotein DARPP-32. DARPP-32 is involved in dopamine and serotonin signaling, is highly expressed in the striatum and prefrontal cortex and is a marker of neuronal dysfunction in HD mice [35,36].",
      "key": "82e455948e6e5afa8683479b3069b408",
      "line": 298,
      "relation": "association",
      "source": 29,
      "target": 67
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "We evaluated several of the well-characterized receptors that are altered in HD including D2DR, GAD65/67, GluR2/3 and 5HT1B.",
      "key": "363dfea667d62dea6797f3a3aab98f59",
      "line": 333,
      "relation": "association",
      "source": 42,
      "target": 71
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "D2DR, GAD65/67 and 5HT1B levels are also altered in the HD transgenic R6/2 mice, but pizotifen treatment did not normalize the levels (data not shown).",
      "key": "ba4946b978f583e0dc57c281de7231fa",
      "line": 358,
      "relation": "association",
      "source": 42,
      "target": 71
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "We evaluated several of the well-characterized receptors that are altered in HD including D2DR, GAD65/67, GluR2/3 and 5HT1B.",
      "key": "929cb776d57a17c3f4ed264dfd9bcfd3",
      "line": 334,
      "relation": "association",
      "source": 46,
      "target": 71
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "D2DR, GAD65/67 and 5HT1B levels are also altered in the HD transgenic R6/2 mice, but pizotifen treatment did not normalize the levels (data not shown).",
      "key": "6d65f16b4cd2060bf1ed8f4411b0f629",
      "line": 359,
      "relation": "association",
      "source": 46,
      "target": 71
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "We evaluated several of the well-characterized receptors that are altered in HD including D2DR, GAD65/67, GluR2/3 and 5HT1B.",
      "key": "dffbe9d09b5c2f5677c5988b93daabd8",
      "line": 335,
      "relation": "association",
      "source": 45,
      "target": 71
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "D2DR, GAD65/67 and 5HT1B levels are also altered in the HD transgenic R6/2 mice, but pizotifen treatment did not normalize the levels (data not shown).",
      "key": "60868671046b7f9b6e5862796ed06115",
      "line": 360,
      "relation": "association",
      "source": 45,
      "target": 71
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "We evaluated several of the well-characterized receptors that are altered in HD including D2DR, GAD65/67, GluR2/3 and 5HT1B.",
      "key": "4c27809899703ca0e736a1d5cae8d355",
      "line": 336,
      "relation": "association",
      "source": 47,
      "target": 71
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "We evaluated several of the well-characterized receptors that are altered in HD including D2DR, GAD65/67, GluR2/3 and 5HT1B.",
      "key": "f3498c59a0943734d73affe38af753f8",
      "line": 337,
      "relation": "association",
      "source": 48,
      "target": 71
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "We evaluated several of the well-characterized receptors that are altered in HD including D2DR, GAD65/67, GluR2/3 and 5HT1B.",
      "key": "63044a6d5cf862d26887e8690249e58a",
      "line": 338,
      "relation": "association",
      "source": 53,
      "target": 71
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ellerby LM",
          "Hughes RE",
          "Papanikolaou T",
          "Sarantos MR"
        ],
        "date": "2012-01-01",
        "db": "PubMed",
        "db_id": "23393546",
        "db_name": "Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.",
        "first": "Sarantos MR",
        "journal": "Journal of Huntington's disease",
        "last": "Hughes RE",
        "pages": "195-210",
        "volume": "1"
      },
      "evidence": "D2DR, GAD65/67 and 5HT1B levels are also altered in the HD transgenic R6/2 mice, but pizotifen treatment did not normalize the levels (data not shown).",
      "key": "5f60b68193245fba4e027fab20a89165",
      "line": 361,
      "relation": "association",
      "source": 53,
      "target": 71
    }
  ],
  "multigraph": true,
  "nodes": [
    {
      "bel": "a(CHEBI:\"3',5'-cyclic AMP\")",
      "concept": {
        "name": "3',5'-cyclic AMP",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "4cdf734bd40326dd8c20c8efe65e611f"
    },
    {
      "bel": "a(CHEBI:\"adenosine triphosphate\")",
      "concept": {
        "name": "adenosine triphosphate",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "5df10c47733716e680d73b520cdc1918"
    },
    {
      "bel": "a(CHEBI:\"dimethyl sulfoxide\")",
      "concept": {
        "name": "dimethyl sulfoxide",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "c99470874b76eb60455e04e85311aa0d"
    },
    {
      "bel": "a(CHEBI:\"neuroprotective agent\")",
      "concept": {
        "name": "neuroprotective agent",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "5f344b06eb517d44a9bd3099d9e4fe3b"
    },
    {
      "bel": "a(CHEBI:U0126)",
      "concept": {
        "name": "U0126",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "311eebb49cff0b875c5a1b6d65a71c18"
    },
    {
      "bel": "a(CHEBI:cetirizine)",
      "concept": {
        "name": "cetirizine",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "8a7b10270d7cce574967b5aaae356199"
    },
    {
      "bel": "a(CHEBI:cyproheptadine)",
      "concept": {
        "name": "cyproheptadine",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "4b8de713e0bf319f863baa752ca65a93"
    },
    {
      "bel": "a(CHEBI:desloratadine)",
      "concept": {
        "name": "desloratadine",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "27a71f7c97f9b1e54b4e61d563f33001"
    },
    {
      "bel": "a(CHEBI:diphenhydramine)",
      "concept": {
        "name": "diphenhydramine",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "6352c39bf1826e3266effc6208660ff7"
    },
    {
      "bel": "a(CHEBI:dopamine)",
      "concept": {
        "name": "dopamine",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "4c950dc480c64069e58998401b2083c1"
    },
    {
      "bel": "a(CHEBI:ketanserin)",
      "concept": {
        "name": "ketanserin",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "732cd0887c149df5cbfc23565f3cd34a"
    },
    {
      "bel": "a(CHEBI:ketotifen)",
      "concept": {
        "name": "ketotifen",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "3191324b671ed9dd50d34297ca6dfb53"
    },
    {
      "bel": "a(CHEBI:levochlorpheniramine)",
      "concept": {
        "name": "levochlorpheniramine",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "5b0afb1f294fa2f4a6263d39b6b533e3"
    },
    {
      "bel": "a(CHEBI:loxapine)",
      "concept": {
        "name": "loxapine",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "24bbc1522eec2bbcc2f592839d5a0521"
    },
    {
      "bel": "a(CHEBI:metergoline)",
      "concept": {
        "name": "metergoline",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "8c36b192864c51af73a241a8fa884264"
    },
    {
      "bel": "a(CHEBI:pizotifen)",
      "concept": {
        "name": "pizotifen",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "1e697ef9e8f7ec58948812d018a315cc"
    },
    {
      "bel": "a(CHEBI:promethazine)",
      "concept": {
        "name": "promethazine",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "0b04d109ba62ff533f7b3a74e7a0600b"
    },
    {
      "bel": "a(CHEBI:risperidone)",
      "concept": {
        "name": "risperidone",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "b845bb28cb099073b51d32e2834da87a"
    },
    {
      "bel": "a(CHEBI:serotonin)",
      "concept": {
        "name": "serotonin",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "257dd38b62d4d98c8f099144b931897e"
    },
    {
      "bel": "a(CHEBI:spiperone)",
      "concept": {
        "name": "spiperone",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "884909ebee12cccec0c96046b2000f98"
    },
    {
      "bel": "a(DRUGBANK:Robalzotan)",
      "concept": {
        "name": "Robalzotan",
        "namespace": "DRUGBANK"
      },
      "function": "Abundance",
      "id": "2090bd4498d519974b4ba785dad5010c"
    },
    {
      "bel": "a(MESH:\"desmethyl-WAY 100635\")",
      "concept": {
        "name": "desmethyl-WAY 100635",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "e9aba4e4f7462747f9b05875c122b3ab"
    },
    {
      "bel": "bp(GO:\"ERK1 and ERK2 cascade\")",
      "concept": {
        "name": "ERK1 and ERK2 cascade",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "75d747a52ba87daccf3b323ab61c4b72"
    },
    {
      "bel": "bp(GO:\"MAPK cascade\")",
      "concept": {
        "name": "MAPK cascade",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "9e09b35ef96c17663f90e4cf6660c167"
    },
    {
      "bel": "bp(GO:\"dopamine receptor signaling pathway\")",
      "concept": {
        "name": "dopamine receptor signaling pathway",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "44be95470b25f7c170076e0450aca1e2"
    },
    {
      "bel": "bp(GO:\"embryo development\")",
      "concept": {
        "name": "embryo development",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "1b73e51cd7feccac729f908f669426b9"
    },
    {
      "bel": "bp(GO:\"mRNA transcription\")",
      "concept": {
        "name": "mRNA transcription",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "690786d5211da9eb8e8b1cd363ac67ad"
    },
    {
      "bel": "bp(GO:\"motor behavior\")",
      "concept": {
        "name": "motor behavior",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "a2dcc4ec00ebc4321e0089baccd16aa5"
    },
    {
      "bel": "bp(GO:\"negative regulation of cell volume\")",
      "concept": {
        "name": "negative regulation of cell volume",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "90e4245b26cb53bba42a07b29514761f"
    },
    {
      "bel": "bp(GO:\"serotonin receptor signaling pathway\")",
      "concept": {
        "name": "serotonin receptor signaling pathway",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "ae9fb3a64de9a0f0fda531f13d08ddcb"
    },
    {
      "bel": "bp(MESH:\"Cell Survival\")",
      "concept": {
        "name": "Cell Survival",
        "namespace": "MESH"
      },
      "function": "BiologicalProcess",
      "id": "c6f26bea83787c63169a3fcb728da799"
    },
    {
      "bel": "complex(a(CHEBI:ketanserin), p(HGNCGENEFAMILY:\"5-hydroxytryptamine receptors, G protein-coupled\"))",
      "function": "Complex",
      "id": "701d849892ece13faadcce8e262e3d9d",
      "members": [
        {
          "bel": "a(CHEBI:ketanserin)",
          "concept": {
            "name": "ketanserin",
            "namespace": "CHEBI"
          },
          "function": "Abundance",
          "id": "732cd0887c149df5cbfc23565f3cd34a"
        },
        {
          "bel": "p(HGNCGENEFAMILY:\"5-hydroxytryptamine receptors, G protein-coupled\")",
          "concept": {
            "name": "5-hydroxytryptamine receptors, G protein-coupled",
            "namespace": "HGNCGENEFAMILY"
          },
          "function": "Protein",
          "id": "514ecb73695321b51a2c3c20db138ac5"
        }
      ]
    },
    {
      "bel": "complex(a(CHEBI:metergoline), p(HGNCGENEFAMILY:\"5-hydroxytryptamine receptors, G protein-coupled\"))",
      "function": "Complex",
      "id": "e5c483f7f74e93eca7d2bd1472822db3",
      "members": [
        {
          "bel": "a(CHEBI:metergoline)",
          "concept": {
            "name": "metergoline",
            "namespace": "CHEBI"
          },
          "function": "Abundance",
          "id": "8c36b192864c51af73a241a8fa884264"
        },
        {
          "bel": "p(HGNCGENEFAMILY:\"5-hydroxytryptamine receptors, G protein-coupled\")",
          "concept": {
            "name": "5-hydroxytryptamine receptors, G protein-coupled",
            "namespace": "HGNCGENEFAMILY"
          },
          "function": "Protein",
          "id": "514ecb73695321b51a2c3c20db138ac5"
        }
      ]
    },
    {
      "bel": "complex(a(CHEBI:promethazine), p(HGNCGENEFAMILY:\"5-hydroxytryptamine receptors, G protein-coupled\"))",
      "function": "Complex",
      "id": "8c9a4fa3a26db8ef27baea50cdb5b29e",
      "members": [
        {
          "bel": "a(CHEBI:promethazine)",
          "concept": {
            "name": "promethazine",
            "namespace": "CHEBI"
          },
          "function": "Abundance",
          "id": "0b04d109ba62ff533f7b3a74e7a0600b"
        },
        {
          "bel": "p(HGNCGENEFAMILY:\"5-hydroxytryptamine receptors, G protein-coupled\")",
          "concept": {
            "name": "5-hydroxytryptamine receptors, G protein-coupled",
            "namespace": "HGNCGENEFAMILY"
          },
          "function": "Protein",
          "id": "514ecb73695321b51a2c3c20db138ac5"
        }
      ]
    },
    {
      "bel": "complex(a(CHEBI:risperidone), p(HGNCGENEFAMILY:\"5-hydroxytryptamine receptors, G protein-coupled\"))",
      "function": "Complex",
      "id": "f70fc3ad99a9854d51d2acf2cf5a76ec",
      "members": [
        {
          "bel": "a(CHEBI:risperidone)",
          "concept": {
            "name": "risperidone",
            "namespace": "CHEBI"
          },
          "function": "Abundance",
          "id": "b845bb28cb099073b51d32e2834da87a"
        },
        {
          "bel": "p(HGNCGENEFAMILY:\"5-hydroxytryptamine receptors, G protein-coupled\")",
          "concept": {
            "name": "5-hydroxytryptamine receptors, G protein-coupled",
            "namespace": "HGNCGENEFAMILY"
          },
          "function": "Protein",
          "id": "514ecb73695321b51a2c3c20db138ac5"
        }
      ]
    },
    {
      "bel": "complex(a(CHEBI:serotonin), p(HGNC:HTR1A))",
      "function": "Complex",
      "id": "6e9a995031ea762ca513acba0aa01057",
      "members": [
        {
          "bel": "a(CHEBI:serotonin)",
          "concept": {
            "name": "serotonin",
            "namespace": "CHEBI"
          },
          "function": "Abundance",
          "id": "257dd38b62d4d98c8f099144b931897e"
        },
        {
          "bel": "p(HGNC:HTR1A)",
          "concept": {
            "name": "HTR1A",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "0ffff62153469b1fb81f349355878fac"
        }
      ]
    },
    {
      "bel": "complex(a(CHEBI:spiperone), p(HGNCGENEFAMILY:\"5-hydroxytryptamine receptors, G protein-coupled\"))",
      "function": "Complex",
      "id": "180496e1de418afef3bc3fc3c837bced",
      "members": [
        {
          "bel": "a(CHEBI:spiperone)",
          "concept": {
            "name": "spiperone",
            "namespace": "CHEBI"
          },
          "function": "Abundance",
          "id": "884909ebee12cccec0c96046b2000f98"
        },
        {
          "bel": "p(HGNCGENEFAMILY:\"5-hydroxytryptamine receptors, G protein-coupled\")",
          "concept": {
            "name": "5-hydroxytryptamine receptors, G protein-coupled",
            "namespace": "HGNCGENEFAMILY"
          },
          "function": "Protein",
          "id": "514ecb73695321b51a2c3c20db138ac5"
        }
      ]
    },
    {
      "bel": "complex(p(HGNC:BDNF), p(HGNC:NTRK2))",
      "function": "Complex",
      "id": "c23ced17e46aebd4d6c6e2d80d0c9fae",
      "members": [
        {
          "bel": "p(HGNC:BDNF)",
          "concept": {
            "name": "BDNF",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "a638d5f84b9678f17c8795852300134a"
        },
        {
          "bel": "p(HGNC:NTRK2)",
          "concept": {
            "name": "NTRK2",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "5873dc57711d54aff73ef2aa04a42017"
        }
      ]
    },
    {
      "bel": "composite(a(CHEBI:pizotifen), p(HGNC:MAPK1, pmod(Ph)), p(HGNC:MAPK3, pmod(Ph)))",
      "function": "Composite",
      "id": "bf44137ee372095d67fcc969127a5cac",
      "members": [
        {
          "bel": "a(CHEBI:pizotifen)",
          "concept": {
            "name": "pizotifen",
            "namespace": "CHEBI"
          },
          "function": "Abundance",
          "id": "1e697ef9e8f7ec58948812d018a315cc"
        },
        {
          "bel": "p(HGNC:MAPK1, pmod(Ph))",
          "concept": {
            "name": "MAPK1",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "ad8ce24b352cb5795d0348447dd5c682",
          "variants": [
            {
              "concept": {
                "name": "Ph",
                "namespace": "bel"
              },
              "kind": "pmod"
            }
          ]
        },
        {
          "bel": "p(HGNC:MAPK3, pmod(Ph))",
          "concept": {
            "name": "MAPK3",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "7b8d42f406cd503d1ef12c374f752ac2",
          "variants": [
            {
              "concept": {
                "name": "Ph",
                "namespace": "bel"
              },
              "kind": "pmod"
            }
          ]
        }
      ]
    },
    {
      "bel": "p(HGNC:BDNF)",
      "concept": {
        "name": "BDNF",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "a638d5f84b9678f17c8795852300134a"
    },
    {
      "bel": "p(HGNC:CASP3)",
      "concept": {
        "name": "CASP3",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "bdb963bb3852568b08002cd7bd9187b1"
    },
    {
      "bel": "p(HGNC:CASP7)",
      "concept": {
        "name": "CASP7",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "97e8e37523825ed2f5cc71ad1fb2dc49"
    },
    {
      "bel": "p(HGNC:DRD2)",
      "concept": {
        "name": "DRD2",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "e010c279847ffd6f70e29bd0a25c24a3"
    },
    {
      "bel": "p(HGNC:EGF)",
      "concept": {
        "name": "EGF",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "7c6e2be826c1c81b55f7f6a99b4bab53"
    },
    {
      "bel": "p(HGNC:EGFR)",
      "concept": {
        "name": "EGFR",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "2d0e5630f4a3b7a0fee65dbf00da20a5"
    },
    {
      "bel": "p(HGNC:GAD1)",
      "concept": {
        "name": "GAD1",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "ee4bb61d66fe0b77b2d39d4ce0c87718"
    },
    {
      "bel": "p(HGNC:GAD2)",
      "concept": {
        "name": "GAD2",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "5f6500fd94067b220d40bf5f1eeaa6e1"
    },
    {
      "bel": "p(HGNC:GRIA2)",
      "concept": {
        "name": "GRIA2",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "6165fe45d1ed83b79e394b29d6bf2991"
    },
    {
      "bel": "p(HGNC:GRIA3)",
      "concept": {
        "name": "GRIA3",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "7cfeb79b26d7b6d972537c39c1a104ed"
    },
    {
      "bel": "p(HGNC:GRM2)",
      "concept": {
        "name": "GRM2",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "34bbd9ab1605bd82f3104ee1fbd200e3"
    },
    {
      "bel": "p(HGNC:GRM3)",
      "concept": {
        "name": "GRM3",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "1ab618603d8c81a440db415015a162dc"
    },
    {
      "bel": "p(HGNC:HRH1)",
      "concept": {
        "name": "HRH1",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "69f2743d270738e05d7832033acc0b09"
    },
    {
      "bel": "p(HGNC:HTR1A)",
      "concept": {
        "name": "HTR1A",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "0ffff62153469b1fb81f349355878fac"
    },
    {
      "bel": "p(HGNC:HTR1B)",
      "concept": {
        "name": "HTR1B",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "5216467dcf729a322b09b62edef41f09"
    },
    {
      "bel": "p(HGNC:HTT)",
      "concept": {
        "name": "HTT",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "b06bc161685303d07e7b94f740920bb7"
    },
    {
      "bel": "p(HGNC:HTT, pmod(CONSO:\"CAG repeats\"))",
      "concept": {
        "name": "HTT",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "5878ef11015a6336bfafc7255b6f926f",
      "variants": [
        {
          "concept": {
            "name": "CAG repeats",
            "namespace": "CONSO"
          },
          "kind": "pmod"
        }
      ]
    },
    {
      "bel": "p(HGNC:MAP2K1)",
      "concept": {
        "name": "MAP2K1",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "b0021b97043b55927d4ad492a5b70bf2"
    },
    {
      "bel": "p(HGNC:MAP2K2)",
      "concept": {
        "name": "MAP2K2",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "18b059c3fde7a51388a9953e2316734a"
    },
    {
      "bel": "p(HGNC:MAPK1)",
      "concept": {
        "name": "MAPK1",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "c2f6ad92491bc72d5a91676150570d38"
    },
    {
      "bel": "p(HGNC:MAPK1, pmod(Ph))",
      "concept": {
        "name": "MAPK1",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "ad8ce24b352cb5795d0348447dd5c682",
      "variants": [
        {
          "concept": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod"
        }
      ]
    },
    {
      "bel": "p(HGNC:MAPK1, pmod(Ph, Tyr, 204))",
      "concept": {
        "name": "MAPK1",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "7f2d5ba9b1cf96fe95547b4a5aaca1d7",
      "variants": [
        {
          "code": "Tyr",
          "concept": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod",
          "pos": 204
        }
      ]
    },
    {
      "bel": "p(HGNC:MAPK3)",
      "concept": {
        "name": "MAPK3",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "3e8019d5b20d209d67726881082657b3"
    },
    {
      "bel": "p(HGNC:MAPK3, pmod(Ph))",
      "concept": {
        "name": "MAPK3",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "7b8d42f406cd503d1ef12c374f752ac2",
      "variants": [
        {
          "concept": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod"
        }
      ]
    },
    {
      "bel": "p(HGNC:MAPK3, pmod(Ph, Thr, 202))",
      "concept": {
        "name": "MAPK3",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "bdd684d19dcabafe2aba66449093d19a",
      "variants": [
        {
          "code": "Thr",
          "concept": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod",
          "pos": 202
        }
      ]
    },
    {
      "bel": "p(HGNC:NF2)",
      "concept": {
        "name": "NF2",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "a0dbd8ed24fe24af8a48b2d75e9afff3"
    },
    {
      "bel": "p(HGNC:NGF)",
      "concept": {
        "name": "NGF",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "433d189daff4b24311745ab14c33bce8"
    },
    {
      "bel": "p(HGNC:NTRK2)",
      "concept": {
        "name": "NTRK2",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "5873dc57711d54aff73ef2aa04a42017"
    },
    {
      "bel": "p(HGNC:PPP1R1B)",
      "concept": {
        "name": "PPP1R1B",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "d4057140e3332c246675d13d2f43d4fe"
    },
    {
      "bel": "p(HGNCGENEFAMILY:\"5-hydroxytryptamine receptors, G protein-coupled\")",
      "concept": {
        "name": "5-hydroxytryptamine receptors, G protein-coupled",
        "namespace": "HGNCGENEFAMILY"
      },
      "function": "Protein",
      "id": "514ecb73695321b51a2c3c20db138ac5"
    },
    {
      "bel": "p(MESH:\"Transport Vesicles\")",
      "concept": {
        "name": "Transport Vesicles",
        "namespace": "MESH"
      },
      "function": "Protein",
      "id": "14821b4addc7375833781939ad7aca84"
    },
    {
      "bel": "path(CONSO:Neurodegeneration)",
      "concept": {
        "name": "Neurodegeneration",
        "namespace": "CONSO"
      },
      "function": "Pathology",
      "id": "e18248b0d7323caa29b448e45437a1e5"
    },
    {
      "bel": "path(DOID:\"Huntington's disease\")",
      "concept": {
        "name": "Huntington's disease",
        "namespace": "DOID"
      },
      "function": "Pathology",
      "id": "a5c9dfe3ed8b0990448319e059ae45cb"
    },
    {
      "bel": "path(DOID:migraine)",
      "concept": {
        "name": "migraine",
        "namespace": "DOID"
      },
      "function": "Pathology",
      "id": "0b5e2adad55000b6964c700415e4a1f1"
    },
    {
      "bel": "path(MESH:\"Energy Metabolism\")",
      "concept": {
        "name": "Energy Metabolism",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "266b2ade166522498effb10b3b6890c9"
    },
    {
      "bel": "path(MESH:\"Striatal Degeneration, Autosomal Dominant\")",
      "concept": {
        "name": "Striatal Degeneration, Autosomal Dominant",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "1f972614df4c9308c7aef9285a8be59e"
    },
    {
      "bel": "path(MESH:Neuropathology)",
      "concept": {
        "name": "Neuropathology",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "4b042241fcef28cb1e62295a6dff900c"
    }
  ]
}